Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

X T L Biopharmaceuticals Ltd

XTLB ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$2.59

▼ -10.38%

Market Cap $6.39M · Vol 449

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.39M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

40.49

Momentum

Beta

1.02

vs Market

52W High

$10.16

74.51% below

52W Low

$2.02

28.22% above

Volume

449

Avg 3.29K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

61.54%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, X T L Biopharmaceuticals Ltd (XTLB) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does XTLB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-11.90%

-12.50%

-4.07%

-27.25%

YTD

+11.64%

-55.03%

-31.84%

-81.76%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-759,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-17.42% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	946.24M

Technical Indicators

50-Day SMA	$2.70
200-Day SMA	$3.02
RSI (14)	40.49
Beta	1.02
52-Week High	$10.16
52-Week Low	$2.02

Volume Today	449
Avg Daily Volume (30D)	3.29K
Relative Volume	0.14x
Volatility (10D)	78.96
Volatility (30D)	86.48
Free Float	61.54%

Analyst Consensus

N/A

Current Price $2.59

Mean Target N/A

52W Low$2.02 52W High$10.16

Current

Target

$2.02 $10.16

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SKMNX1

ISINUS98386D4060

CountryIsrael

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

X T L Biopharmaceuticals Ltd (Xenograft Technologies Ltd) is an Israel-based biopharmaceutical company engaged in acquisition and development of pharmaceutical drugs for treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.